Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Inari Medical Inc. reports strong Q1 earnings and unveils promising growth opportunities

Inari Medical Inc. delivered strong Q1 performance with notable revenue growth and a focus on achieving sustained operating profitability by the first half of 2024. The company's expansion efforts, clinical trials, and new product releases present promising opportunities for future growth. However, strategic management and market positioning will be crucial in addressing challenges and maintaining competitive strength.

Inari Medical reports record Q2 revenue and eyes international expansion

Inari Medical's Q2 2023 earnings call showcased strong financial performance, successful product launches, and a positive outlook for the company's growth drivers. While facing competitive pressures and product development challenges, Inari is strategically focused on addressing unmet patient needs and expanding its international presence, with opportunities for growth in the CBD market and Asian markets.

Inari Medical reports robust Q3 performance and strategic LimFlow acquisition

Inari Medical's Q3 2023 performance reflects strong revenue growth, improved operating income, and a positive net income. The acquisition of LimFlow presents strategic advantages, including a first-mover position and revenue guidance increase. However, challenges lie in the impact on operating profit targets and the need for careful revenue planning amidst cost and margin declines.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

IRVINE, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) announced today that its management team will participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020.

Inari Medical to Participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum

IRVINE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 12, 2020. On the same day, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.

Inari Medical to Announce Third Quarter 2020 Financial Results

DexCom

These fast-growing medical device companies could outperform the S&P 500 over the next several years.

Why I Just Bought These 2 Under-the-Radar Stocks

IRVINE, Calif., Sept.  21, 2020  (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the interim results from the FLASH study have been accepted for presentation in a late-breaking clinical science session at TCT Connect. The FLASH study is evaluating the safety and effectiveness of the FlowTriever System for treatment of pulmonary embolism (PE) in a real-world patient population. Interim data on the first 230 patients enrolled at 19 US sites will be presented in the late-breaking session.

Inari Medical Prospective Clinical Data on the FlowTriever System to be Presented in Late-Breaking Session at TCT Connect

IRVINE, Calif., Sept.  17, 2020  (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Operating Officer, effective September 1, 2020.  In his expanded role, Mr. Hykes will now have responsibility for Research, Product Development, Manufacturing, Operations, Quality and Regulatory, in addition to the Commercial functions.

Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer

IRVINE, Calif., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the management team is scheduled to speak at the following upcoming investor conferences.

Inari Medical to Participate in Upcoming Investor Conferences

Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q2 2020 Results - Earnings Call Transcript

Hot IPO stock Inari Medical late Tuesday reported earnings and sales that beat expectations, but in the regular session shares reversed after hitting an all-time high for a third straight day.
The post Hot IPO Stock Inari Medical Posts Big Sales Gain; Beats Expectations appeared first on Investor's Business Daily.

Hot IPO Stock Inari Medical Posts Big Sales Gain; Beats Expectations

IRVINE, Calif., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2020.

Inari Medical Reports Second Quarter 2020 Financial Results

IRVINE, Calif., July  29, 2020  (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced the company will be participating in the upcoming Canaccord Genuity 40th Annual Virtual Growth Conference.

Inari Medical to Present at the Canaccord Genuity 40th Annual Growth Conference

IRVINE, Calif., July  28, 2020  (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the second quarter of 2020 after market close on Tuesday, August 11, 2020. On the same day, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights.

Inari Medical to Announce Second Quarter 2020 Financial Results

Its medical devices offer promising clinical benefits over the competition.

Why You Need This Medical-Device Company on Your Radar

IRVINE, Calif., May  27, 2020  (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the closing of its initial public offering of 9,432,949 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 1,230,384 additional shares of common stock, at the initial public offering price of $19.00 per share. The gross proceeds to Inari, before deducting underwriting discounts and commissions and offering expenses, were approximately $179.2 million.  Inari’s common stock is listed on the Nasdaq Global Select Market under the symbol "NARI."

Inari Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Shares of Inari Medical Inc. NARI, +114.07% rocketed out of the gate Friday, as they opened for trading at prices that were more than double the initial public offering price.

Inari Medical's stock blasts off, trades more than double the IPO price

Inari Medical Inc. increased that number of shares it was selling in its initial public offering, which priced late Thursday above the expected range.

News for Inari Medical Stock (NARI)